Saturday, 7 November 2026European Markets
ExploreSearch
ViaNews EU
IndexesMarket

BEL 20 Bullish By 2% In The Last 5 Sessions

Loading stream...

(VIANEWS) - BEL 20 (^BFX) has been up by 2.6% for the last 5 sessions. At 13:50 EST on Tuesday, 4 July, BEL 20 (^BFX) is €3,570.19.

Concerning BEL 20's yearly highs and lows, it's 9.18% up from its 52-week low and 9.9% down from its 52-week high.

Volatility

BEL 20's last week, last month's, and last quarter's current intraday variation average was a positive 0.45%, a negative 0.13%, and a positive 0.58%, respectively.

BEL 20's highest amplitude of average volatility was 0.46% (last week), 0.45% (last month), and 0.58% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BEL 20's is considered to be oversold (<=20).

More news about BEL 20 (^BFX).

Categories

IndexesMarket

Tags

INDICES Price UpBEL 20IndexIndex NowPrice Up^BFXIndicesWorld Indices
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com